SCHEMBL12413705

SCHEMBL12413705

CC(C)CC(=O)NCC1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.51
TSHR P16473 1/20 0.49
EPHX1 P07099 2/20 0.44
EPHX2 P34913 1/20 0.44
HTR4 Q13639 4/20 0.43
KDM1A O60341 1/20 0.43
ANPEP P15144 1/20 0.41
ERAP2 Q6P179 1/20 0.41
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39
MAPK14 Q16539 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
PREP P48147 1/20 0.37
CPN1 P15169 1/20 0.37
CPB2 Q96IY4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6147426 0.98 ALOX15 (0.50) ALOX15TSHREPHX1EPHX2HTR4
SCHEMBL12413714 0.90 SLC6A1 (0.43) ALOX15TSHREPHX1EPHX2HTR4
SCHEMBL4515125 0.87 TDP1 (0.48) TP53SMN1; SMN2MAPK14TDP1PREP
SCHEMBL11890389 0.84 EPHX1 (0.48) EPHX1EPHX2TP53SMN1; SMN2TDP1
SCHEMBL9575 0.82 EPHX1 (0.52) EPHX1EPHX2SMN1; SMN2
SCHEMBL12413707 0.81 CPN1 (0.42) TSHREPHX1TP53SMN1; SMN2PREP
SCHEMBL19116737 0.81 TDP1 (0.42) TP53SMN1; SMN2MAPK14TDP1PREP
SCHEMBL6190098 0.80 ALOX15 (0.56) ALOX15TSHREPHX1EPHX2HTR4
SCHEMBL21730544 0.80 ALOX15 (0.46) ALOX15TSHREPHX1EPHX2HTR4
SCHEMBL12764359 0.79 NPC1 (0.39) HTR4TP53SMN1; SMN2MAPK14TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 ALOX15 448/4885TSHR 1418/4885EPHX1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.